ALSUntangled #67: rituximab

Xiaoyan Li; Carmel Armon; Paul Barkhaus; Benjamin Barnes; Michael Benatar; Tulio Bertorini; Mark Bromberg; Gregory T. Carter; Jesse Crayle; Merit Cudkowicz; Mazen Dimachkie; Eva L. Feldman; Jonathan Glass; Jill Goslinga; Terry Heiman-Patterson; Sartaj Jhooty; Rachel Lichtenstein; Isaac Lund; Christopher Mcdermott; Gary Pattee; Kaitlyn Pierce; Dylan Ratner; Kristiana Salmon; Paul Wicks; Richard Bedlack

doi:10.1080/21678421.2022.2122845

ALSUntangled #67: rituximab

Xiaoyan Li, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Tulio Bertorini, Mark Bromberg, Gregory T. Carter, Jesse Crayle, Merit Cudkowicz, Mazen Dimachkie, Eva L. Feldman, Jonathan Glass, Jill Goslinga, Terry Heiman-Patterson, Sartaj Jhooty, Rachel Lichtenstein, Isaac Lund, Christopher Mcdermott, Gary PatteeKaitlyn Pierce, Dylan Ratner, Kristiana Salmon, Paul Wicks, Richard Bedlack

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.

Original language	English
Pages (from-to)	544-547
Number of pages	4
Journal	Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume	24
Issue number	5-6
DOIs	https://doi.org/10.1080/21678421.2022.2122845
State	Published - 2023

Keywords

ALS
neuroinflammation
off-label treatment
rituximab

Access to Document

10.1080/21678421.2022.2122845

Cite this

Li, X., Armon, C., Barkhaus, P., Barnes, B., Benatar, M., Bertorini, T., Bromberg, M., Carter, G. T., Crayle, J., Cudkowicz, M., Dimachkie, M., Feldman, E. L., Glass, J., Goslinga, J., Heiman-Patterson, T., Jhooty, S., Lichtenstein, R., Lund, I., Mcdermott, C., ... Bedlack, R. (2023). ALSUntangled #67: rituximab. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24(5-6), 544-547. https://doi.org/10.1080/21678421.2022.2122845

@article{1f72f582f43246f7aed2a5f3eac62888,

title = "ALSUntangled #67: rituximab",

abstract = "ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.",

keywords = "ALS, neuroinflammation, off-label treatment, rituximab",

author = "Xiaoyan Li and Carmel Armon and Paul Barkhaus and Benjamin Barnes and Michael Benatar and Tulio Bertorini and Mark Bromberg and Carter, {Gregory T.} and Jesse Crayle and Merit Cudkowicz and Mazen Dimachkie and Feldman, {Eva L.} and Jonathan Glass and Jill Goslinga and Terry Heiman-Patterson and Sartaj Jhooty and Rachel Lichtenstein and Isaac Lund and Christopher Mcdermott and Gary Pattee and Kaitlyn Pierce and Dylan Ratner and Kristiana Salmon and Paul Wicks and Richard Bedlack",

note = "Publisher Copyright: {\textcopyright} 2022 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.",

year = "2023",

doi = "10.1080/21678421.2022.2122845",

language = "English",

volume = "24",

pages = "544--547",

journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",

issn = "2167-8421",

publisher = "Informa Healthcare",

number = "5-6",

}

Li, X, Armon, C, Barkhaus, P, Barnes, B, Benatar, M, Bertorini, T, Bromberg, M, Carter, GT, Crayle, J, Cudkowicz, M, Dimachkie, M, Feldman, EL, Glass, J, Goslinga, J, Heiman-Patterson, T, Jhooty, S, Lichtenstein, R, Lund, I, Mcdermott, C, Pattee, G, Pierce, K, Ratner, D, Salmon, K, Wicks, P & Bedlack, R 2023, 'ALSUntangled #67: rituximab', Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 24, no. 5-6, pp. 544-547. https://doi.org/10.1080/21678421.2022.2122845

TY - JOUR

T1 - ALSUntangled #67

T2 - rituximab

AU - Li, Xiaoyan

AU - Armon, Carmel

AU - Barkhaus, Paul

AU - Barnes, Benjamin

AU - Benatar, Michael

AU - Bertorini, Tulio

AU - Bromberg, Mark

AU - Carter, Gregory T.

AU - Crayle, Jesse

AU - Cudkowicz, Merit

AU - Dimachkie, Mazen

AU - Feldman, Eva L.

AU - Glass, Jonathan

AU - Goslinga, Jill

AU - Heiman-Patterson, Terry

AU - Jhooty, Sartaj

AU - Lichtenstein, Rachel

AU - Lund, Isaac

AU - Mcdermott, Christopher

AU - Pattee, Gary

AU - Pierce, Kaitlyn

AU - Ratner, Dylan

AU - Salmon, Kristiana

AU - Wicks, Paul

AU - Bedlack, Richard

PY - 2023

Y1 - 2023

N2 - ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.

AB - ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.

KW - ALS

KW - neuroinflammation

KW - off-label treatment

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=85138163435&partnerID=8YFLogxK

U2 - 10.1080/21678421.2022.2122845

DO - 10.1080/21678421.2022.2122845

M3 - Review article

C2 - 36106861

AN - SCOPUS:85138163435

SN - 2167-8421

VL - 24

SP - 544

EP - 547

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

IS - 5-6

ER -

ALSUntangled #67: rituximab

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this